Tablo 3.
Comparisons of functioning levels, duration of treatment, number of episodes and hospitalisations of patients according to the drugs used
| MS (41,2%; n=68) | MS+AP (50,9%; n=84) | AP (7,9%; n=13) | x2 | p* | |
|---|---|---|---|---|---|
| BDFQ | Median (IR) | Median (IR) | Median (IR) | ||
| Emotional functioning | 8 (3) | 7 (4) | 7 (3) | 1.168 | 0.558 |
| Cognitive functioning | 10 (3) | 10 (5) | 10 (5) | 0.372 | 0.830 |
| Sexual functioning | 8 (4) | 8 (6) | 9 (3) | 1.882 | 0.390 |
| Sense of stigmatization | 9 (5) | 8 (4) | 10 (3) | 3.509 | 0.173 |
| Introversion | 7 (2) | 6 (3)a | 6 (3) | 13.774 | 0.001 |
| Domestic relations | 15 (5) | 13 (5)a | 13 (6) | 8.249 | 0.016 |
| Relationships with friends | 11 (4) | 10 (3) | 10 (4) | 2.316 | 0.314 |
| Participation in community activities | 12 (6) | 11 (5) | 11 (6) | 0.176 | 0.916 |
| Daily activities and hobbies | 12 (4) | 12 (4) | 14 (4) | 1.631 | 0.442 |
| Taking initiative and using the potential | 5 (2) | 4.5 (2) | 4 (2) | 2.041 | 0.360 |
| Work | 10 (4) | 10 (3) | 10 (3) | 0.974 | 0.614 |
| Clinical and treatment data | x2 | p* | |||
| Number of manic episodes | 2 (2) | 3 (3)b | 1 (2) | 6.304 | 0.043 |
| Total number of episodes | 4 (4) | 4 (4) | 2 (3)d | 9.733 | 0.008 |
| Number of hospitalizations | 1 (2) | 2 (2)c | 1 (2) | 8.914 | 0.012 |
| Duration of use of current treatment (months) | 36 (72) | 36 (60) | 12 (16)d | 8.117 | 0.017 |
*
Kruskal Wallis Test was conducted, IR: Interquartile range; BDFQ: Bipolar Disorder Functioning Questionnaire; MS: Mood stabilizer; MS-AP: At least one antipsychotic in addition to the mood stabilizers; AP: Atypical antipsychotic
a
Significantly lower compared to the group using MS,
b
Significantly higher compared to the group using AP,
c
Significantly higher compared to the group using MS+AP,
d
Significantly lower compared to the groups using MS and MS+AP